Obstructive Airways DiseaseThe Emerging Role of Systemic Inflammation in Chronic Obstructive Pulmonary DiseaseTran, Betty MD; Kalhan, Ravi MD, MSAuthor Information From the Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Supported by the Northwestern Memorial Foundation. Address correspondence to: Ravi Kalhan, MD, MS, Division of Pulmonary/Critical Care, Northwestern University Feinberg School of Medicine, 676 N. St. Clair, #1400, Chicago, IL 60611. E-mail: email@example.com. Clinical Pulmonary Medicine: March 2008 - Volume 15 - Issue 2 - p 55-62 doi: 10.1097/CPM.0b013e3181671a46 Buy Metrics AbstractIn Brief The systemic effects of chronic obstructive pulmonary disease (COPD) are becoming increasingly apparent. Systemic inflammatory markers are of interest in mediating these systemic effects, and studies have shown that increased levels of inflammatory markers such as fibrinogen and C-reactive protein are associated not only with COPD severity, but also with the risk of cardiovascular morbidity and mortality. In addition, higher levels of fibrinogen and C-reactive protein are associated with lower lung function in individuals with no evidence of lung disease. Cigarette smoke is traditionally considered to be a risk factor for COPD and a potential stimulus for systemic inflammation, but COPD does not develop in all smokers. As such, other mechanisms are likely involved. Certain individuals may exhibit an “inflammatory phenotype” and have a greater predisposition to mounting an excessive inflammatory response to a certain stimulus. Therapy with inhaled corticosteroids has shown a decrease in systemic markers of inflammation and a trend towards improving lung function and mortality. Chronic obstructive pulmonary disease (COPD) has increasingly been recognized as a systemic disease with multiple comorbidities. We explore the link between systemic inflammation and the comorbidities seen in COPD, and discuss hypotheses regarding the mechanisms behind the systemic inflammatory response in COPD. © 2008 Lippincott Williams & Wilkins, Inc.